Physician profile
Rasheed A Gbadegesin
NPI 1205951720
$49,719.03
in general payments reported to CMS, 2019-2025
15 companies · $15K in 2025
The $15K reported for 2025 was more than what 99% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $1,600 · 2021: $150 · 2022: $4,361 · 2023: $16K · 2024: $12K · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $31K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,000 · Travel and Lodging: $2,130 · Food and Beverage: $1,135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $31,342.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,000.00 |
| Travel and Lodging | $2,130.12 |
| Food and Beverage | $1,135.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $24,978.95 | 2020-2024 | |
| Vertex Pharmaceuticals Incorporated | $15,775.44 | 2022-2025 | |
| Novo Nordisk INC | $5,208.00 | 2025 | Rivfloza |
| Calliditas Therapeutics US INC. | $2,617.72 | 2025 | Tarpeyo |
| Astrazeneca Uk Limited | $800.00 | 2025 | |
| Alexion Pharmaceuticals, INC. | $150.00 | 2021 | |
| Apellis Pharmaceuticals, INC. | $138.62 | 2025 | |
| Horizon Therapeutics Plc | $32.00 | 2022 | |
| Novo Nordisk Health Care Ag | $18.30 | 2025 | Rivfloza |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rasheed Gbadegesin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.